Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways

Journal of Alzheimer's Disease

Volumn 13, Issue 2, 2008, Pages 111-122

  Dolga, Amalia M ^a   Nijholt, Ingrid M ^a   Ostroveanu, Anghelus ^a   Ten Bosch, Quirine ^a   Luiten, Paul G M ^a   Eisel, Ulrich L M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Excitotoxicity; Neuronal culture; NF B; PKB Akt; Statin

Indexed keywords

GLUTAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEVINOLIN; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; HYPOCHOLESTEROLEMIC AGENT; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CELL CULTURE; CELL ISOLATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EMBRYO; EXCITOTOXICITY; ISCHEMIA; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; AGED; ALZHEIMER DISEASE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; HUMAN; METABOLISM; PHOSPHORYLATION; STROKE;

AGED; ALZHEIMER DISEASE; ANIMALS; ANTICHOLESTEREMIC AGENTS; DISEASE MODELS, ANIMAL; GLUTAMIC ACID; HUMANS; LOVASTATIN; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIGNAL TRANSDUCTION; STROKE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44849104999     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2008-13201     Document Type: Article

References (54)

1. A. Endo, The discovery and development of HMG-CoA reductase inhibitors, J Lipid Res 33 (1992), 1569-1582.
2. Y. Kunieda, K. Nakagawa, H. Nishimura, H. Kato, N. Ukimura, S. Yano, H. Kawano, S. Kimura, M. Nakagawa and H. Tsuji, HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells, Thromb Res 110 (2003), 227-234.
3. B.P. Leung, N. Sattar, A. Crilly, M. Prach, D.W. McCarey, H. Payne, R. Madhok, C. Campbell, J.A. Gracie, F.Y. Liew and I.B. McInnes, A novel anti-inflammatory role for simvastatin in inflammatory arthritis, J Immunol 170 (2003), 1524-1530.
4. M.B. Harris, M.A. Blackstone, S.G. Sood, C. Li, J.M. Goolsby, V.J. Venema, B.E. Kemp and R.C. Venema, Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors, Am J Physiol Heart Circ Physiol 287 (2004), H560-H566.
5. O. Hernandez-Perera, D. Perez-Sala, J. Navarro-Antolin, R. Sanchez-Pascuala, G. Hernandez, C. Diaz and S. Lamas, Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells, J Clin Invest 101 (1998), 2711-2719.
6. C.J. Vaughan and N. Delanty, Neuroprotective properties of statins in cerebral ischemia and stroke, Stroke 30 (1999), 1969-1973.
7. W.A. Maltese, Posttranslational modification of proteins by isoprenoids in mammalian cells, FASEB J 4 (1990), 3319-3328.
8. M.C. Seabra, Membrane association and targeting of prenylated Ras-like GTPases, Cell Signal 10 (1998), 167-172.
9. D.L. Sparks, M. Sabbagh, D. Connor, H. Soares, J. Lopez, G. Stankovic, S. Johnson-Traver, C. Ziolkowsky and P. Browne, Statin therapy in Alzheimer's disease, Acta Neurol Scand Suppl 185 (2006), 78-86.
10. S.S. Petanceska, S. DeRosa. V. Olm, N. Diaz, A. Sharma, T. Thomas-Bryant, M. Pappolla and L.L. Refolo, Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci 19 (2002), 155-161.
11. R. Perry, J.C. Collins, H. Wiener, R. Acton and R.C.P. Go, The role of TNF and its receptors in Alzheimer's disease, Neurobiol Aging 22 (2001), 873-883.
12. U.L.M. Eisel, K. Biber and P.G.M. Luiten, Life and death of nerve cells: Therapeutic cytokine signaling pathways, Curr Signal Transduc Ther 1 (2006), 133-146.
13. D.J. MacEwan, TNF receptor subtype signalling: differences and cellular consequences, Cell Signal 14 (2002), 477-492.
14. D.J. MacEwan, TNF ligands and receptors-a matter of life and death, Br J Pharmacol 135 (2002), 855-875.
15. H. Wajant, K. Pfizenmaier and P. Scheurich, Tumor necrosis factor signaling, Cell Death Differ 10 (2003), 45-65.
16. V. Fontaine, S. Mohand-Said, N. Hanoteau, C. Fuchs, K. Pfizenmaier and U. Eisel, Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2, J Neurosci 22 (2002), RC216: 1-7.
17. L.A. Madge, M.R. Sierra-Honigmann and J.S. Pober, Apoptosis-inducing agents cause rapid shedding of tumor necrosis factor receptor 1 (TNFR1), J Biol Chem 274 (1999), 13643-13649.
18. T. Hehlgans, C. Seitz, C. Lewis and D.N. Mannel, Hypoxic upregulation of TNF receptor type 2 expression involves NF-IL-6 and is independent of HIF-1 or HIF-2, Interferon Cytokine Res 21 (2001), 757-762.
19. L. Marchetti, M. Klein, K. Schlett, K. Pfizenmaier and U.L.M. Eisel, Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation, J Biol Chem 289 (2004), 32869-32881.
20. M.R. Hynd, H.L. Scott and P.R. Dodd, Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease, Neurochem Int 45 (2004), 583-595.
21. T. Nubel, S. Schmitt, B. Kaina and G. Fritz, Lovastatin stimulates p75 TNF receptor (TNFR2) expression in primary human endothelial cells, Int Mol Med 16 (2005), 1139-1145.
22. A. Zacco, J. Togo, K. Spence, A. Ellis, D. Lloyd, S. Furlong and T. Piser, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity, J Neurosci 23 (2003), 11104-11111.
23. J.K. Lim, J.C. Lee, Y.H. Lee, I.Y. Choi, Y.K. Oh, H.S. Kim, J.S. Park and W.K. Kim, Simvastatin prevents oxygen and glucose deprivation/reoxygenation- induced death of cortical neurons by reducing the production and toxicity of 4-hydroxy-2E-nonenal, J Neurochem 97 (2006), 140-150.
24. S.L. Erickson, F.J. de Sauvage, K. Kikly, K. Carver-Moore, S. Pitts-Meek, N. Gillett, K.C. Sheehan, R.D. Schreiber, D.V. Goeddel and M.W. Moore, Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice, Nature 372 (1994), 560-563.
25. K. Pfeffer, T. Matsuyama, T.M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P.S. Ohashi, M. Kronke and T.W. Mak, Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection, Cell 73 (1993), 457-467.
26. J. Rothe, W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz and H. Bluethmann, Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes, Nature 364 (1993), 798-802.
27. T. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J Immunol. Methods 65 (1983), 55-63.
28. J.A. Gustin, O.N. Ozes, H. Akca, R. Pincheira, L.D. Mayo, Q. Li, J.R. Guzman, C.K. Korgaonkar and D.B. Donner, Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation, J Biol Chem 279 (2004), 1615-1620.
29. G. Song, G. Ouyang and S. Bao, The activation of Akt/PKB signaling pathway and cell survival, J Cell Mol Med 9 (2005), 59-71.
30. T.F. Franke, D.R. Kaplan and L.C. Cantley, PI3K: downstream AKTion blocks apoptosis, Cell 88 (1997), 435-437.
31. M.A. Lawlor and D.R. Alessi, PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114 (2001), 2903-2910.
32. S. Memet, NF-kappaB functions in the nervous system: from development to disease, Biochem Pharm 72 (2006), 110-1195.
33. S. Ghosh and M. Karin, Missing pieces in the NF-kappaB puzzle, Cell 109, (2002), S81-96.
34. S.T. Whiteside and A. Israel, I kappa B proteins: structure, function and regulation, Semin Cancer Biol 8 (1997), 75-82.
35. L. Wang, P. Reinach and L. Lu, TNF-a promotes cell survival through stimulation of K+ channel and NFκB activity in corneal epithelial cells, Exp Cell Res 311 (2005), 39-48.
36. T. Harkany, I. Abraham, W. Timmerman, G. Laskay, B. Toth, M. Sasvari, C. Konya, J.B. Sebens, J. Korf, C. Nyakas, M. Zarandi, K. Soos, B. Penke and P.G.M. Luiten, Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis, Eur J Neurosci 12 (2000), 2735-2745.
37. M.P. Mattson, Pathways towards and away from Alzheimer's disease, Nature 430 (2004), 631-639.
38. Y. Kureishi, Z. Luo, I. Shiojima, A. Bialik, D. Fulton, D.J. Lefer, W.C. Sessa and K. Walsh, The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals, Nat Med 6 (2000), 1004-1010.
39. A. Skaletz-Rorowski, M. Lutchman, Y. Kureishi, D.J. Lefer, J.R. Faust and K. Walsh, HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells, Cardiovasc Res 57 (2003), 253-264.
40. J. Rothe, H. Bluethmann, R. Gentz, W. Lesslauer and M. Steinmetz, Genomic organization and promoter function of the murine tumor necrosis factor receptor beta gene, Mol Immunol 30 (1993), 165-175.
41. L.M. Rasmussen, P.R. Hansen, M.T. Nabipour, P. Olesen, M.T. Kristiansen and T. Ledet, Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells, Biochem J 360 (2001), 363-370.
42. S.M. Santee and L.B. Owen-Schaub, Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization, J Biol Chem 271 (1996), 21151-21159.
43. M.P. Mattson and S. Camandola, NF-kappaB in neuronal plasticity and neurodegenerative disorders, J Clin Invest 107 (2001), 247-254.
44. P. Yang, J.L. Wiser, J.J. Peairs, J.N. Ebright, Z.J. Zavodni, C.B. Rickman and G.J. Jaffe, Human RPE Expression of cell survival factors, Invest Ophthalmol Vis Sci 46 (2005), 1755-1764.
45. M. Grilli, M. Pizzi, M. Memorandum and P. Spano, Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation, Science 274 (1996), 1383-1385.
46. B. Cheng, S. Christakos and M.P. Mattson, Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis, Neuron 1 (1994), 139-153.
47. S.W. Barger, D. Hörster, K. Furukawa, Y. Goodman, J. Krieglstein and M.P. Mattson, Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation, Proc Natl Acad Sci 92 (1995), 9328-9332.
48. A.J. Bruce, W. Boling, M.S. Kindy, J. Peschon, P.J. Kraemer M.K. Carpenter, F.W. Holtsberg and M.P. Mattson, Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors, Nat Med 2 (1996), 788-794.
49. R. Gnad, B. Kaina and G. Fritz, Rho GTPases are involved in the regulation of NF-kappaB by genotoxic stress, Exp Cell Res 264 (2001), 244-249.
50. T. Nubel, W. Dippold, H. Kleinert, B. Kaina and G. Fritz, Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion, FASEB J 18 (2004), 140-142.
51. L. Sironi, C. Banfi, M. Brioschi, P. Gelosa, U. Guerrini, E. Nobili, A. Gianella, R. Paoletti, E. Tremoli and M. Cimino, Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment, Neurobiol Dis 22 (2006), 445-451.
52. B. Echternacher, W. Falk, D.N. Männel and P.H. Krammer, Requirement of endogenous tumor necrosis factor/cachectin fo recovery from experimental peritonitis, J Immunol 145 (1990), 3762-3766.
53. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.M. Warnica, J.M. Arnold, C.C. Wun, B.R. Davis and E. Braunwald, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med 335 (1996), 1001-1009.
54. T. Vollmer and I. Singh, Statins for multiple sclerosis, The Lancet 364 (2004), 412-413.